HUE034641T2 - Methods for reducing binge or compulsive eating - Google Patents
Methods for reducing binge or compulsive eating Download PDFInfo
- Publication number
- HUE034641T2 HUE034641T2 HUE11844637A HUE11844637A HUE034641T2 HU E034641 T2 HUE034641 T2 HU E034641T2 HU E11844637 A HUE11844637 A HU E11844637A HU E11844637 A HUE11844637 A HU E11844637A HU E034641 T2 HUE034641 T2 HU E034641T2
- Authority
- HU
- Hungary
- Prior art keywords
- eating
- binge
- patient
- treatment
- naltrexone
- Prior art date
Links
- 235000005686 eating Nutrition 0.000 title claims description 20
- 238000000034 method Methods 0.000 title description 8
- 206010020710 Hyperphagia Diseases 0.000 title description 6
- 235000020830 overeating Nutrition 0.000 title description 6
- 208000010235 Food Addiction Diseases 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 10
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 206010010219 Compulsions Diseases 0.000 claims description 2
- YFVKHKCZBSGZPE-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-2-(propylamino)propan-1-one Chemical compound CCCNC(C)C(=O)C1=CC=C2OCOC2=C1 YFVKHKCZBSGZPE-UHFFFAOYSA-N 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 241000764238 Isis Species 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 238000009958 sewing Methods 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000014679 binge eating disease Diseases 0.000 description 152
- 208000032841 Bulimia Diseases 0.000 description 99
- 206010004716 Binge eating Diseases 0.000 description 96
- 229960003086 naltrexone Drugs 0.000 description 65
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 65
- 229960001058 bupropion Drugs 0.000 description 60
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 60
- 239000012730 sustained-release form Substances 0.000 description 31
- 238000013268 sustained release Methods 0.000 description 29
- 235000013305 food Nutrition 0.000 description 24
- 239000000203 mixture Substances 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 19
- 235000014632 disordered eating Nutrition 0.000 description 16
- 208000024714 major depressive disease Diseases 0.000 description 15
- 230000007423 decrease Effects 0.000 description 13
- 208000008589 Obesity Diseases 0.000 description 12
- 206010033307 Overweight Diseases 0.000 description 12
- 235000020824 obesity Nutrition 0.000 description 12
- 208000030814 Eating disease Diseases 0.000 description 11
- 208000019454 Feeding and Eating disease Diseases 0.000 description 11
- 206010006550 Bulimia nervosa Diseases 0.000 description 10
- 230000009467 reduction Effects 0.000 description 9
- 206010056465 Food craving Diseases 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002996 emotional effect Effects 0.000 description 8
- 230000004584 weight gain Effects 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 239000006186 oral dosage form Substances 0.000 description 6
- 208000020016 psychiatric disease Diseases 0.000 description 6
- 230000006399 behavior Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000000116 mitigating effect Effects 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000001916 dieting Nutrition 0.000 description 4
- 230000037228 dieting effect Effects 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 230000020595 eating behavior Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000025748 atypical depressive disease Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 208000024732 dysthymic disease Diseases 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 206010012374 Depressed mood Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 206010029897 Obsessive thoughts Diseases 0.000 description 2
- 208000037063 Thinness Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 206010048828 underweight Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- IKBZAUYPBWFMDI-UHFFFAOYSA-N 5-bromo-4-methoxy-7-methyl-2,3-dihydro-1h-indene Chemical compound C1=C(Br)C(OC)=C2CCCC2=C1C IKBZAUYPBWFMDI-UHFFFAOYSA-N 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010016374 Feelings of worthlessness Diseases 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 206010018671 Grandiosity Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007301 Night Eating Syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229960004367 bupropion hydrochloride Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000021061 dietary behavior Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000015255 meat loaf Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229960000858 naltrexone hydrochloride Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41935410P | 2010-12-03 | 2010-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE034641T2 true HUE034641T2 (en) | 2018-02-28 |
Family
ID=46172302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE11844637A HUE034641T2 (en) | 2010-12-03 | 2011-12-02 | Methods for reducing binge or compulsive eating |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20130252995A1 (enExample) |
| EP (1) | EP2646011B1 (enExample) |
| JP (1) | JP2014508717A (enExample) |
| KR (1) | KR20140035319A (enExample) |
| CN (1) | CN103298462A (enExample) |
| AR (2) | AR084093A1 (enExample) |
| AU (3) | AU2011336298B2 (enExample) |
| BR (1) | BR112013015957B1 (enExample) |
| CA (1) | CA2819003A1 (enExample) |
| CL (1) | CL2013001565A1 (enExample) |
| CY (1) | CY1119560T1 (enExample) |
| DK (1) | DK2646011T3 (enExample) |
| ES (1) | ES2647232T3 (enExample) |
| HR (1) | HRP20171678T1 (enExample) |
| HU (1) | HUE034641T2 (enExample) |
| IL (1) | IL226483A0 (enExample) |
| LT (1) | LT2646011T (enExample) |
| MX (1) | MX350304B (enExample) |
| NO (1) | NO2646011T3 (enExample) |
| PL (1) | PL2646011T3 (enExample) |
| PT (1) | PT2646011T (enExample) |
| RS (1) | RS56548B1 (enExample) |
| RU (1) | RU2620913C2 (enExample) |
| SI (1) | SI2646011T1 (enExample) |
| SM (1) | SMT201700537T1 (enExample) |
| TW (2) | TWI536986B (enExample) |
| WO (1) | WO2012075453A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101167579B1 (ko) | 2003-04-29 | 2012-07-27 | 오렉시젠 세러퓨틱스 인크. | 체중감량용 조성물 |
| PT2135603E (pt) | 2005-11-22 | 2013-04-03 | Orexigen Therapeutics Inc | Composições e métodos para aumentar a sensibilidade à insulina |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| WO2008060964A2 (en) | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| ES2762113T3 (es) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor |
| PL4104824T3 (pl) | 2012-06-06 | 2025-11-12 | Nalpropion Pharmaceuticals Llc | Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2197250C2 (ru) * | 2000-10-30 | 2003-01-27 | Соколовский Сергей Ростиславович | Способ лечения наркоманий |
| KR101167579B1 (ko) | 2003-04-29 | 2012-07-27 | 오렉시젠 세러퓨틱스 인크. | 체중감량용 조성물 |
| US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| WO2008060964A2 (en) | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
| DE602007005402D1 (de) | 2006-11-09 | 2010-04-29 | Orexigen Therapeutics Inc | Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht |
| GB2447949B (en) * | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
| US8318813B2 (en) * | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| US20100317572A1 (en) * | 2007-12-20 | 2010-12-16 | Neurosearch A/S | Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound |
| KR102385359B1 (ko) * | 2010-11-08 | 2022-04-11 | 오메로스 코포레이션 | Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료 |
-
2011
- 2011-12-02 NO NO11844637A patent/NO2646011T3/no unknown
- 2011-12-02 RS RS20171107A patent/RS56548B1/sr unknown
- 2011-12-02 US US13/991,372 patent/US20130252995A1/en not_active Abandoned
- 2011-12-02 RU RU2013127420A patent/RU2620913C2/ru active
- 2011-12-02 LT LTEP11844637.6T patent/LT2646011T/lt unknown
- 2011-12-02 PT PT118446376T patent/PT2646011T/pt unknown
- 2011-12-02 PL PL11844637T patent/PL2646011T3/pl unknown
- 2011-12-02 CA CA2819003A patent/CA2819003A1/en not_active Abandoned
- 2011-12-02 TW TW100144461A patent/TWI536986B/zh active
- 2011-12-02 HU HUE11844637A patent/HUE034641T2/en unknown
- 2011-12-02 HR HRP20171678TT patent/HRP20171678T1/hr unknown
- 2011-12-02 TW TW105105528A patent/TW201735912A/zh unknown
- 2011-12-02 MX MX2013006070A patent/MX350304B/es active IP Right Grant
- 2011-12-02 SI SI201131336T patent/SI2646011T1/en unknown
- 2011-12-02 SM SM20170537T patent/SMT201700537T1/it unknown
- 2011-12-02 WO PCT/US2011/063170 patent/WO2012075453A1/en not_active Ceased
- 2011-12-02 BR BR112013015957-0A patent/BR112013015957B1/pt active IP Right Grant
- 2011-12-02 AR ARP110104511A patent/AR084093A1/es not_active Application Discontinuation
- 2011-12-02 KR KR1020137017316A patent/KR20140035319A/ko not_active Withdrawn
- 2011-12-02 ES ES11844637.6T patent/ES2647232T3/es active Active
- 2011-12-02 DK DK11844637.6T patent/DK2646011T3/da active
- 2011-12-02 AU AU2011336298A patent/AU2011336298B2/en active Active
- 2011-12-02 CN CN2011800595435A patent/CN103298462A/zh active Pending
- 2011-12-02 EP EP11844637.6A patent/EP2646011B1/en active Active
- 2011-12-02 JP JP2013542227A patent/JP2014508717A/ja active Pending
-
2013
- 2013-05-21 IL IL226483A patent/IL226483A0/en unknown
- 2013-05-31 CL CL2013001565A patent/CL2013001565A1/es unknown
-
2017
- 2017-04-27 AU AU2017202793A patent/AU2017202793B2/en active Active
- 2017-11-14 CY CY20171101188T patent/CY1119560T1/el unknown
-
2018
- 2018-06-04 AU AU2018203921A patent/AU2018203921A1/en not_active Abandoned
-
2021
- 2021-06-02 US US17/336,546 patent/US20210283126A1/en active Pending
- 2021-12-23 AR ARP210103652A patent/AR124497A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017202793B2 (en) | Methods for Reducing Binge or Compulsive Eating | |
| Keefe et al. | Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study | |
| US10403170B2 (en) | Methods of treating overweight and obesity | |
| US9248123B2 (en) | Methods of providing weight loss therapy in patients with major depression | |
| Harit et al. | Randomized, double-blind, placebo-controlled, clinical study of Passiflora incarnata in participants with stress and sleep problems | |
| Preston et al. | Medical and Psychosocial Considerations in Older Adults | |
| Thomas | Causes of protein-energy malnutrition | |
| HK1188148B (en) | Methods for reducing binge or compulsive eating | |
| HK1188148A (en) | Methods for reducing binge or compulsive eating | |
| Garrett | Perimenopause: The Savvy Sister's Guide to Hormone Harmony | |
| Watkins et al. | Physical Health in the Context of Mental Health | |
| Oparil | A 42-year-old man with hypertension | |
| Bruehl et al. | Trait anger and blood pressure recovery following acute pain: evidence for opioid-mediated effects | |
| Hirsch et al. | Comprehensive Geriatric Assessment | |
| Jayasiri et al. | A comparative clinical study on the efficacy of navaka guggulu and amritadya guggulu in the management of sthaulya (overweight and obesity) | |
| Gammack | 13 Geriatric Assessment and Its Interaction with Nutrition | |
| Roller et al. | Disease state management: Parkinson's disease | |
| Van der Westhuizen | Obesity: evidence-based pharmacy practice | |
| Robson et al. | Physical health care and serious mental illness | |
| Khosravi et al. | Causes of failure to control hypertension in people over 65 years of age | |
| Pavcic et al. | Diabetics attitudes to recommended nutritional changes | |
| Vera | Education and diabetes | |
| SWARAJ | Toxic waist | |
| Landau et al. | The New Truth about Menopause: Straight Talk about Treatments and Choices from Two Leading Women Doctors | |
| Usman et al. | AWARENESS AND LIFE STYLE MODIFICATION AMONG PATIENTS OF HYPERTENSION GETTING HEALTH CARE FACILITIES AT LIAQUAT NATIONAL HOSPITAL KARACHI |